Shots:
- Recordati has entered into a collaboration & license deal with Moderna to develop & commercialize mRNA-3927 globally for the treatment of propionic acidemia
- As per the deal, Moderna will continue to co-develop mRNA-3927 with Recordati, while Recordati will lead global commercialization if approved. In exchange, Moderna will receive $50M upfront, ~$110M in development & regulatory milestones, plus additional commercial & sales milestones, with tiered royalties
- mRNA-3927 is in clinical development, with interim data published in Nature, showing early clinical improvement, plus a registrational study now fully enrolled, targeting reduced metabolic decompensation events, with readout expected by the end of 2026
Ref: Globenewswire |  Image: Recordati & Moderna  | Press Release
Related News: Moderna Reports the CHMP Positive Opinion on mNEXSPIKE to Protect Against COVID-19
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
